All‐cause mortality · individuals with sickle cell disease who have had a stroke who have had long‐term red cell transfusions to prevent another stroke
It is very uncertain whether long‐term red cell transfusion changes all‐cause mortality compared with hydroxyurea and phlebotomy (very low certainty).
1 finding from 1 review
Adverse events associated with transfusion · individuals with sickle cell disease who have had a stroke who have had long‐term red cell transfusions to prevent another stroke
1 finding from 1 review
Incidence of TIA · individuals with sickle cell disease who have had a stroke who have had long‐term red cell transfusions to prevent another stroke
It is very uncertain whether long‐term red cell transfusion changes incidence of TIA compared with hydroxyurea and phlebotomy (very low certainty).
1 finding from 1 review
Serious adverse events as a result of sickle cell‐related complications · individuals with sickle cell disease who have had a stroke who have had long‐term red cell transfusions to prevent another stroke
It is very uncertain whether long‐term red cell transfusion changes serious adverse events as a result of sickle cell‐related… compared with hydroxyurea and phlebotomy (very low certainty).
1 finding from 1 review
Measures of neurological impairment ‐ not reported · individuals with sickle cell disease who have had a stroke who have had long‐term red cell transfusions to prevent another stroke
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life ‐ not reported · individuals with sickle cell disease who have had a stroke who have had long‐term red cell transfusions to prevent another stroke
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events associated with transfusion · individuals with sickle cell disease who are at risk of a primary stroke who have not had previous long‐term red cell transfusions
It is very uncertain whether long‐term red cell transfusion changes adverse events associated with transfusion compared with no transfusion (very low certainty).
1 finding from 1 review
TIA · individuals with sickle cell disease who are at risk of a primary stroke who have not had previous long‐term red cell transfusions
It is very uncertain whether long‐term red cell transfusion changes TIA compared with no transfusion (very low certainty).
1 finding from 1 review
Serious adverse events as a result of sickle cell‐related complications · individuals with sickle cell disease who are at risk of a primary stroke who have not had previous long‐term red cell transfusions
Long‐term red cell transfusion may leads to lower serious adverse events as a result of sickle cell‐related… compared with no transfusion (low certainty).
1 finding from 1 review
Neurological impairment · individuals with sickle cell disease who are at risk of a primary stroke who have not had previous long‐term red cell transfusions
1 finding from 1 review
Quality of life · individuals with sickle cell disease who are at risk of a primary stroke who have not had previous long‐term red cell transfusions
1 finding from 1 review
Stroke · individuals with sickle cell disease who are at risk of a primary stroke who have had long‐term red cell transfusions to prevent a stroke
It is very uncertain whether long‐term red cell transfusion changes clinical stroke compared with no transfusion (very low certainty).
1 finding from 1 review
All‐cause mortality · individuals with sickle cell disease who are at risk of a primary stroke who have had long‐term red cell transfusions to prevent a stroke
It is very uncertain whether long‐term red cell transfusion changes all‐cause mortality compared with no transfusion (very low certainty).
1 finding from 1 review
Live birth or ongoing pregnancy · women undergoing pituitary suppression in assisted reproduction
Long protocol (GnRHa until HCG) showed no clear difference in live birth and ongoing pregnancies per woman randomised compared with long protocol (extend GnRHa 12 days after HCG) (low certainty).
1 finding from 1 review
Clinical pregnancy rate · women undergoing pituitary suppression in assisted reproduction
Long protocol (GnRHa until HCG) showed no clear difference in clinical pregnancies per woman randomised compared with long protocol (extend GnRHa 12 days after HCG) (low certainty).
1 finding from 1 review
Clinical pregnancies Number of clinical pregnancies per woman randomised · women undergoing pituitary suppression in assisted reproduction
Long protocol continued GnRH agonist showed no clear difference in clinical pregnancies Number of clinical pregnancies per woman… compared with long protocol stop GnRH agonist (low certainty).
1 finding from 1 review
Ongoing pregnancy / live birth rate per woman · women undergoing pituitary suppression in assisted reproduction
Long protocol continued GnRH agonist showed no clear difference in live birth and ongoing pregnancies Number of live births or ongoing… compared with long protocol stop GnRH agonist (low certainty).
1 finding from 1 review
Laxation response: risk of spontaneous rescue‐free bowel movements in the short terma · people with cancer irrespective of whether they were receiving palliative care opioid‐induced bowel dysfunction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Laxation response: risk of spontaneous rescue‐free bowel movements in the medium termb · people with cancer irrespective of whether they were receiving palliative care opioid‐induced bowel dysfunction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Laxation response: patient assessment of change in bowel status at the end of trial · people with cancer irrespective of whether they were receiving palliative care opioid‐induced bowel dysfunction
1 finding from 1 review